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Abstract

Introduction

Alterations in thyroid hormone status and the administration
of radiographic contrast agents can markedly influence iodothyronine metabolism and, in particular, the activity of type I
5'-deiodinase (51I). In the present studies, the mechanisms
responsible for these effects have been reassessed. As previously reported, the addition of iopanoic acid (1OP) to broken
cell preparations resulted in a competitive pattern of 5DI inhibition. However, the in vivo administration to rats of IOP or
3,3',5'-triiodothyronine (rT3) resulted in a noncompetitive pattern of inhibition of 51)I in the liver, kidney, and thyroid gland,
whereby marked decreases in maximal enzyme velocity (Vx)
were noted, with no change in the value of the Michaelis-Menten constant. In rats rendered hyperthyroid by the injection of
3,5,3'-triiodothyronine (T3), 5DI activity was significantly increased in the liver and the kidney. The administration of IOP
to these thyrotoxic animals resulted in a rapid loss of enzyme
activity characterized by an approximate 80% decrease in 5DI
V.,,, values in both tissues. Furthermore, this inhibitory effect
persisted for longer than 60 h after a single IOP injection. IOP
administration also decreased 51)I V.,. levels in the thyroid
gland by 52%. In other experiments, treatment of intact Reuber
FAO hepatoma cells with IOP or rT3 induced a rapid decrease
in 5DI V.,., levels. In cells treated with cycloheximide, these
agents enhanced the rate of disappearance of enzyme activity
by > 12-fold, indicating a predominant effect on accelerating
the rate of enzyme inactivation and/or degradation. These
studies demonstrate that iodothyronines and other iodinated
compounds have complex regulatory effects on 5DI that entail
alterations in the rates of both enzyme activation and inactivation. The previously accepted concept that rT3 and IOP impair
thyroxine (T4) to T3 conversion in vivo by acting as competitive
inhibitors is an oversimplification. Rather, the clinically beneficial effects of administering these agents to patients with
hyperthyroidism may result primarily from the rapid and prolonged inactivation of 51)I which occurs in the thyroid gland
and peripheral tissues.

The hyperthyroid state associated with Graves' disease is characterized by a marked increase in the rate of both the thyroidal
secretion and the peripheral production of 3,5,3'-triiodothyronine (T3)' (1). The resultant elevations in the circulating and
tissue T3 concentrations lead to functional changes in a number of organ systems and thus produce the characteristic signs
and symptoms of this disorder.
Alterations in thyroid hormone status also have important
and direct "autoregulatory" effects on the cellular processes
that metabolize these hormones (2). In the rat, hyperthyroidism results in a marked increase in the rate of "local" T3
production in the liver (3, 4). This effect is secondary, in part,
to an increase in activity of type I 5'-deiodinase (51DI), the
principal enzymatic process responsible for hepatic thyroxine
(T4) to T3 conversion (5). In contrast to this activating effect of
thyroid hormones on 5'DI in the liver (and kidney [6]), type II
5'-deiodinase (5'DII) activity in the anterior pituitary gland and
central nervous system is suppressed in hyperthyroid animals,
and T3 neogenesis in these tissues is markedly decreased (2, 3).
The autoregulatory effects of thyroid hormones on 51DI and
5'DII thus differ significantly. As a consequence, the 5'DI
present in the liver and kidney is likely to be the principal
process mediating the extrathyroidal conversion of T4 to T3 in
the hyperthyroid state.
Radiographic contrast agents such as iopanoic acid (IOP)
and sodium ipodate (NaIp) inhibit T4 to T3 conversion in man
(7-9) and experimental animals (10-12), and offer an alternative to the thionamides in the treatment of Graves' disease ( 13,
14). When administered to hyperthyroid patients, these agents
induce a marked decrease in the serum T3 concentration
which occurs more rapidly than that noted after the administration of stable iodine (15) or 6-n-propyl-2-thiouracil (PTU)
(16). The rapidity with which radiographic contrast agents
lower T3 levels may be of considerable clinical importance. In
a recent study of thyrotoxic patients with severe cardiac manifestations, the amelioration of clinical symptoms after NaIp
administration paralleled the fall in serum T3 levels; significant
improvements in several cardiovascular parameters were
noted as early as 3 h after a single dose (17).
In tissue homogenates, IOP and NaIp act as competitive
inhibitors of both 5DI (18-20) and 51)II (21, 22), and this has
previously been assumed to be the mechanism whereby they
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1. Abbreviations used in this paper: BW, body weight; 5DI, type I
iodothyronine 5'-deiodinase; 5DII, type II iodothyronine 5'-deiodinase; IOP, iopanoic acid; MMI, methimazole; NaIp, sodium ipodate;
prot, protein; PTU, 6-n-propyl-2-thiouracil; rT3, 3,3',5'-triiodothyronine; T3, 3,5,3'-triiodothyronine; T4, thyroxine; TSH, thyroid-stimulating hormone.

inhibit T3 neogenesis in vivo. We have recently demonstrated,
however, that these agents inhibit T4 to T3 conversion in the
anterior pituitary gland and cerebral cortex in vivo by noncompetitively and irreversibly inactivating the 5D11 enzyme
(23). This process of inactivation involves a unique mechanism of enzyme regulation that may be initiated by the direct
interaction of ligands (e.g., substrates such as T4 or 3,3',5'triiodothyronine [reverse T3, rT3J, or competitive inhibitors
such as 1OP) with the 5DII active site. Furthermore, this ligand-induced inactivation of 5DII is modulated by the cellular thiol/disulfide balance (23).
These findings regarding the regulation of 5DII prompted
us to investigate the mechanisms whereby thyroid hormones,
radiographic contrast agents, and sulfhydryl oxidizing agents
regulate 5DI in several tissues of the rat. Our results demonstrate that 5DI is regulated in a manner considerably more
complex than previously believed, and that this enzymatic
process in the liver, kidney, and thyroid gland is subject to
ligand-induced inactivation in a fashion analogous to that
previously delineated for 5DIL.

Methods
Materials. Iodothyronines were obtained from Henning Co. (West
Berlin, FRG) or Calbiochem-Behring Diagnostics, American Hoechst
Corp. (La Jolla, CA) and were of the highest purity commercially
available. 1OP was kindly provided by the Sterling-Winthrop Research
Institute (Rensselaer, NY). 3'- or 5'-'251I-labeled rT3 (SA 830 ACi/Ag)
was obtained from New England Nuclear (Boston, MA).
Animal experiments. Male Sprague-Dawley rats (175-200 g) were
used in all experiments and were obtained from Charles River Breeding Laboratory, Inc. (Wilmington, MA). Animals were housed under
conditions of controlled lighting and temperature and were given free
access to food. In one experiment, rats were rendered hypothyroid and
goitrous by the inclusion of 200 Ag/ml methimazole (MMI) in their
drinking water for 4 wk. Animals so treated stopped gaining weight
after 10 d, and the wet weight of their individual thyroid glands was
increased threefold over that of euthyroid control animals (control,
14±1 mg/gland; MMI, 41±2; P < 0.001). In other experiments, thyroidectomized rats (with the parathyroid glands reimplanted) were
obtained from the same supplier and were used for experiments 8 wk
after surgery. Before killing, animals received single or multiple injections of T3, rT3, T4, and/or IOP according to the experimental protocols described below. Control animals received equivalent volumes of
the vehicle solution (propylene glycol, 0.1 N NaOH, 0.25 M NaCl
[50:42:8 vol/vol]).
Renal, hepatic, and/or thyroidal tissue were harvested from individual animals and homogenized in 10 vol of assay buffer (0.25 M
sucrose, 0.02 M Tris/HCI, pH 7.0, 1 mM EDTA) using either a motorized Teflon pestle (kidney and liver) or a ground glass homogenizer
(thyroid). The homogenates were centrifuged at 1,000 g and the supernatant diluted 1:40 to 1:800 with assay buffer. All preparative procedures were performed at 0-4°C. 5DI activity was determined immediately in the diluted supernatant by a kinetic analysis in which the
production rate of 23I- from 125I-rT3 was measured in the presence of
20 mM dithiothreitol using a modification of the methods of Leonard
and Rosenberg (24) and McCann et al. (25). At each concentration of
'25I-rT3, duplicate aliquots of the diluted supernatant (40 Al containing
0.5-10 gg of protein) were incubated at 37°C for 40 min and the
reaction was then terminated by the addition of 12 Al of an ice-cold
BSA solution (40 mg/ml) plus 120 Ml of an ice-cold 20% TCA solution.
Other aliquots were kept at 0-40C and terminated immediately after
adding the 1251-rT3 to determine basal '25I- content. The 125I- present
in the supernatant fraction of the terminated reaction mixture was
-

separated by ion-exchange chromatography using an AG5OW-X8

(H+) column (mesh size, 200-400; bed size, 0.7 X 4 cm; Bio-Rad
Laboratories, Richmond, CA) equilibrated and washed with 10% acetic acid. The '25I- in the column effluent

was

counted in

a
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counter. As quantified by paper chromatography or TLC (see below),

equal molar quantities of 3,3'-diiodothyronine and I- were produced
from '25I-rT3 in the homogenates of kidney, liver, and thyroid tissue.
No '25I- was released in tissue-free incubations performed at 370C.
5'DI activity was expressed as picomoles of '25I- released per minute
per milligram protein after multiplying by a factor of two to correct for
the random labeling of 25I-rT3 at the 3' or 5' position. Kinetic data were
analyzed by double reciprocal and Eadie-Hofstee plots (26) using the
average substrate concentration during the 40-min incubation period
as suggested by Lee and Wilson (27). The value of the Ki was calculated
by replotting the slope of the double reciprocal plot vs. the concentration of competitive inhibitor. On such a plot, the K, value is represented by the negative value of the x-intercept (28).
Cell culture experiments. Reuber FAO rat hepatoma cells were a
gift from Dr. Lee A. Witters (Dartmouth Medical School, Hanover,
NH) and were routinely grown in 75-cm2 plastic flasks and 60- and
100-mm plastic culture dishes using RPMI 1640 culture medium supplemented with 5% FCS, 5% calf serum, 100 U/ml penicillin, and 100
Ag/ml streptomycin. In some studies, cells were transferred and maintained for 24-48 h in serum-free RPMI 1640 medium before experimentation. Other experiments were performed with cells incubated in
serum-free medium which was also glucose-free. Experiments were
performed with cells at the confluent stage of growth and 24 h after the
last medium change. At various times after the addition of agents to the
FAO cell cultures, the medium was aspirated and the cells were washed
twice with PBS. The cells were then harvested by scraping with a
rubber policeman into assay buffer and sonicated using a sonic dismembrator (Artek Systems Corp., Dynatech Corp., Farmingdale, NY).
In experiments in which cells were incubated with diamide, the wash
buffer and assay buffer contained 5 mM DTT. The sonicate was then
centrifuged at 14,000 g and aliquots of the supernatant (40 Ml containing 25-100 Mg of protein) were used immediately for the determination of 51DI activity as described above. All preparative procedures
were carried out at 0-40C. As quantified by paper chromatography,
equal molar quantities of 3,3'-T2 and I- were produced from '251I-rT3 in
the FAO cell sonicates.
Other determinations. The effect of cycloheximide on protein synthesis in FAO cells was determined by quantitating [3H]leucine incorporation into TCA-precipitated material according to the method of
Scornik et al. (29).
Ascending paper chromatography was performed using a tertial
amyl alcohol/2 N ammonium hydroxide (1:1) solvent system as described by Galton and Hiebert (30).
TLC was performed as described by van Doom et al. (31) using 20
X 20 cm aluminum sheets coated with Silicagel-60 (E. Merck, Darmstadt, FRG) and a solvent system consisting of 25% ammonium-methanol-chloroform (3:20:40 vol/vol). Rf values for the iodinated compounds of interest were: 0.31 for rT3, 0.42 for 3,3'-T2, and 0.67 for I-.
Protein concentrations were determined by the method of Lowry et
al. (32). Aliquots of tissue samples containing DTT were precipitated
with TCA before the determination of protein content (33).
All results are given as the mean±SE. Statistical analysis was performed using the paired and unpaired t test with the Bonferroni correction applied when multiple comparisons were made (34). Alterna-

t test was used when
made with a control group (35).

tively, Dunnett's

multiple comparisons

were

Results

Regulation of S'DI in kidney and liver. As previously reported
by other investigators (18-20), IOP acted as a competitive
inhibitor of 5DI in vitro. Thus, the addition of increasing
concentrations of IOP to kidney homogenates from a euthyroid animal resulted

in a

series of kinetic

curves

that inter-
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sected at the y-axis on a double reciprocal plot (Fig. 1). Slopereplots of such data (Fig. 1, inset) from two experiments
yielded Ki values of 8 and 10 gM.
The in vivo administration of IOP to thyroidectomized rats
resulted in an entirely different pattern of inhibition. Double
reciprocal plots of kinetic data obtained in renal homogenates
from individual animals injected 3 h previously with IOP revealed a decrease in Vn, with no change in the value of the
Kim indicating a noncompetitive mechanism of inhibition
(Fig. 2). As shown in Table I, IOP dosages of 0.04 and 4
mg/I00 g body weight (BW) inhibited 5DI Vm,, values by 52
and 66%, respectively. The finding that Km values were unchanged in this (Table I), as well as in subsequent experiments,
indicates that the amount of IOP carried over into the in vitro
5DI assay system was insufficient to cause competitive inhibition of '25I-rT3 deiodination.
The effects of the chronic administration of T3, rT3, and
1OP on the regulation of 5DI in the kidney and liver were
examined in a second group of thyroidectomized rats (Fig. 3).
Twice daily, injections of rT3 (50 jtg/lOO g BW) or IOP (100
,ug/I00 g BW) resulted in a marked and significant decrease in
Vm.. values in both tissues. In contrast, the administration of
T3 in a dose designed to render the animals hyperthyroid (0.6
,ug/100 g BW, twice daily) increased 5DI activity to levels
10-fold greater than those observed in hypothyroid animals
and two- to threefold greater than those present in a control
group of euthyroid rats of the same age. The ability of rT3 and
1OP to antagonize the stimulating effects of T3 were also examined (Fig. 3). 5)DI activity in hyperthyroid animals was unchanged after a single injection of rT3 (50 g/lI00 g BW) or TOP
(100 ,ug/100 g BW). However, injection of a single larger dose
of lOP (4 mg/100 g BW), comparable in amount to that used
in treating hyperthyroid patients with Graves' disease, resulted
in a 78 and 85% decrease in V.. values in the liver and kidney,
respectively. This inhibition by IOP in thyrotoxic animals resulted in levels of 5DI activity that were less than or similar to

0

5

'/rT3 ,IIL)Figure 2. Effect of the in vivo administration of IOP on kidney 5DI
activity. Thyroidectomized rats were given an intraperitoneal injection of lOP (4 mg/lOO g BW) or vehicle (control) and killed 3 h later.
Kidney homogenates from individual animals were then prepared
and 5DI activity was determined in the diluted supernatant fractions. A double reciprocal plot of kinetic data from two representative animals demonstrates a noncompetitive pattern of inhibition.

those noted in euthyroid control rats. Again, Km values in all
groups were unchanged (Fig. 3), which suggests that the observed alterations in enzyme activity represented changes in
the cellular content of active enzyme molecules. Kinetic data
obtained in the liver from representative, individual animals
from several of the treatment groups are shown in Fig. 4. On
such plots, the Vma. value is represented by the yintercept,
whereas the Km value is equal to the negative value of the
slope (26).
The time course of the in vivo inhibitory effects of IOP on
5DI in hyperthyroid animals was investigated in another experiment in which rats were treated chronically with T3 (1
Asg/I00 g BW, s.c., twice daily) and then were administered a
single intravenous dose of IOP (4 mg/100 g BW) at 5, 12, 24,
or 60 h before killing (Fig. 5). In the 24- and 60-h treatment
groups, T3 administration was continued until 12 h before
killing. Hyperthyroid animals again demonstrated significantly higher 5DI activity in the liver and kidney when compared with euthyroid control rats. IOP administration resulted
in an inhibition of Vm., values in both tissues which was rapid
in onset and prolonged in duration. The maximal inhibitory
effects of 77 and 84% in liver and kidney, respectively, were
similar to those noted previously and occurred at 5-12 h after
Table I. Effects of the In Vivo Administration of IOP on S'DI
Activity in the Kidney of Hypothyroid Rats
Treatment

n

5

'/rT3

'

(IM)-1

Figure 1. Effects of IOP on 5DI activity in a broken kidney cell
preparation. A kidney homogenate was prepared from a euthyroid
animal and the diluted supernatant fraction was used to determine
51)I activity. IOP, in the final concentrations indicated, was added to
aliquots of the assay mixture before the quantitation of enzyme activity. A double reciprocal plot of the kinetic data demonstrates a
competitive pattern of inhibition. A replot of the slope of the double
reciprocal plots vs. the IOP concentration (inset) demonstrated a Ki
value of 8 jM. Similar results were obtained in a second experiment.
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Control

lOP (0.04)t
1OP (4)

6
5
5

V.,

K.

pmol/min * mg protein

AM

13.3±0.7
6.4±0.6§

0.10±0.01
0.10±0.01
0.11±0.03

4.5±0.5§

* n, number of rats.
IlOP, in a single dose of 0.04 or 4 mg/I00 g BW, i.p., was administered 3 h before killing to rats that had been thyroidectomized 8 wk
earlier. Data represent the mean±SE.
§ P < 0.001 vs. control (Dunnett's t test).
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Figure 3. Effects of the chronic and acute in vivo administration of
rT3, lOP, and T3 on 5DI activity in the (A) liver and (B) kidney.
Thyroidectomized rats received twice daily subcutaneous injections
for 4 d according to the following protocol: (a) control, vehicle solug BW; (c)l0P,
00r
4 1
tion; gg/I00
(b) rT3, 50
g/I00 g BW; (d) T3
treatment, 0.6 ,sg/100 g BW. Animals were killed 12 h after the last
injection and 51)1 activity was quantified in diluted supernatant fractions of liver and kidney homogenates. 6 h before killing, T3-treated
animals received a single intravenous injection of vehicle (veh), rT3
(50ugIg!00 g BW), or 1OP (10 M~g or 4 mg/lI00 g BW). A group of
euthyroid control rats of the same age served as an additional control
group. Results depict the mean±SE of four to five animals per group.
The insets at the base of each bar report the mean Km value of each
group expressed in Mmol/liter. *P < 0.01 vs. thyroidectomized control group; IP < 0.01 vs. T3 vehicle treatment group; IP < 0.05 vs.
thyroidectomized control; 'IP.< 0.01 vs. T3 vehicle treatment group
and vs. euthyroid control group.

the IOP injection. Although partial recovery of 5DI activity
was noted at the 60-h time point, V.,,, values were still significantly less (36 and 18% in liver and kidney, respectively) than
those noted in the corresponding hyperthyroid control group.
Effects of IOP on S'DI activity in the thyroid gland. 51DI
activity has been reported to be increased in the thyroid gland
of patients with Graves' disease (36, 37). Similar increases in
activity have been noted in the thyroid glands of rodents that
were administered thyroid-stimulating hormone (TSH) (38) or
Igs from patients with Graves' disease (39), or rendered hypothyroid by the chronic administration of MMI (40). To determine whether radiographic contrast agents inhibit 5DI Vm..
levels in thyroid tissue, rats made goitrous by the inclusion of
MMI in their drinking water were injected intravenously with
a single dose of IOP (4 mg/100 g BW) and then killed 5 or 12 h
later. In contrast to a previous report (40), 5DI activity in the
thyroid glands of MMI-treated rats was not different from that
determined in euthyroid control rats ofthe same age (Table II).
IOP administration, however, resulted in a significant decrease
in Vmax levels at both time points. At 5 h after the IOP injec-

~

~~~~
O

I

II~~~~~~~~s0

500

1000

V/[rrT31

Figure 4. Hepatic 51)I activity, as analyzed by Eadie-Hofstee plots,
of representative, individual animals from the experiment depicted
in Fig. 3. On these plots, the -intercept represents the Vma. value,
and the negative value of the slope indicates the Km. A noncompetitive pattern of inhibition is demonstrated. Concentrations of rT3 on
the abscissa are expressed in gmol/liter. Tx, thyroidectomized.

tion, 5DI activity was decreased by 29% (P < 0.05), whereas at
the 12-h time point activity was reduced by 52% (P < 0.005).
IOP administration did not alter Km values in either treatment
group. Thus, as is the case in the liver and the kidney, radiographic contrast agents inhibit 51DI in the thyroid gland in vivo
by a noncompetitive mechanism.
Regulation of S'DI in the Reuber FAO hepatoma cell line.
The suitability of Reuber FAO hepatoma cells to serve as a
model system for studying the regulation of 5DI activity was
investigated. Phenolic ring deiodinase activity was easily demonstrated in FAO cell sonicates using 251I-rT3 as substrate.
Characterization of this deiodinating process revealed the following: (a) 125I- release from '25I-rT3 was thiol-dependent with
maximal product formation noted at DTT concentrations of
5-20 mM; (b) no 1251- production was noted in cell sonicates
incubated at 0-40C or in sonicates previously heated to 80'C
for 30 min; (c) 1251- production varied linearly with sonicate
protein content up to 2.5 mg/ml; (d) as determined by paper
chromatography, equal quantities of I- and 3,3'-diiodothyronine were formed from 251I-rT3; (e) in the presence of 20 mM
dithiothreitol, PTU at a concentration of 1 mM inhibited 1251production by > 99%; (f ) using 1 nM '25I-T3 as a substrate, no
phenolic or tyrosyl ring deiodinating activity could be demonstrated in cell sonicates under routine assay conditions; (g)
'251- formation decreased somewhat with time of assay incubation; calculated deiodinase activity at the end of a 40-min
incubation period was decreased by 30% from that determined during a 10-min incubation. However, to allow accurate quantitation of reaction velocity under a variety of experimental conditions, a 40-min incubation period was typically
used. Using '251-rT3 as substrate in sonicates prepared from
FAO cells that were maintained in serum-free medium, saturable reaction kinetics were demonstrated for phenolic ring
-
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deiodinase activity. In seven experiments, mean Km and Vma.
values were 0.22±0.02 gM and 5.3±1.1 pmol 125i- formed/
min * mg protein, respectively. Reuber FAO hepatoma cells
thus manifest a 5'-deiodinase process that has the typical characteristics of the type I activity normally found in rat liver and

A Liver

100

kidney.
.E

Km
090809

5
200

07

.11 12

08

12
24
Time after IOP (h)

06

60

B Kidney

0

>t4I*O
°
111a
100

H

24

_

5
Euthyroid

12
24
Time after IOP(h)
U Hyperthyroid

_

60

El Hyperthyoid + TOP]

Figure 5. Time course of the inhibitory effect of IOP on 5)DI activity
in the (A) liver and (B) kidney of hyperthyroid rats. Euthyroid rats
were rendered hyperthyroid by the subcutaneous injection of T3 (1
,gg/ I00 g BW twice daily) for 4 d. The hyperthyroid rats were then
administered a single, intravenous dose of vehicle solution or IOP (4
mg/100 g BW) and killed 5, 12, 24, or 60 h later. T3 injections were
continued until 12 h before killing. Animals receiving a subcutaneous injection of vehicle twice daily for 4 d served as a euthyroid control group. Results depict the mean±SE of four to five animals per
group. The insets at the base of each bar report the mean Km value of
each group expressed in Mmol/liter. *P < 0.01 vs. corresponding
hyperthyroid, vehicle group; *P < 0.05 vs. corresponding hyperthyroid, vehicle group.

The addition of IOP or rT3 to the culture medium of FAO
cells maintained under serum-free conditions resulted in a
dose- and time-dependent inhibition of 5DI activity that was
characterized by a decrease in Vm. with no change in the Km
value (Fig. 6). In three experiments in which cells were incubated for 18-40 h with 0.5 MM 1OP, Vm,. values were decreased by an average of 51±5%. At higher IOP concentrations
(10 ,uM), inhibition was as great as 88%. The inhibitory effects
of rT3 were approximately equipotent to those of IOP. Vma,
values were decreased by 36±6, 46±8, and 90±1% in three
experiments in which cells were incubated with rT3 at concentrations of 0.1, 1, and 3.3 MM, respectively. In other studies, a
similar time course of 5DI inhibition was noted for IOP and
rT3; inhibitory effects were half-maximal at 3 h and maximal
at 20 h after addition of the agents to the culture medium.
The dependency of the inhibitory effects of IOP and rT3 on
protein synthesis was investigated using FAO cells incubated
with cycloheximide (Fig. 7). The addition of 50 Mg/ml cycloheximide to the culture medium inhibited [3H]leucine incorporation into TCA-precipitated material by > 95%. In spite of
this inhibition of protein synthesis, cycloheximide treatment
for 6 h decreased 5DI activity in FAO cells by only 5±2% (n
= 4 experiments) compared with untreated control cells. Cycloheximide did not block the inhibitory effects of rT3 and IOP
on 5DI activity. The addition of rT3 (1 AM) or IOP (10 MAM) to
cycloheximide-treated cells resulted in a 42±9 and 53±10%
decrease (P < 0.01 for either group vs. cycloheximide treatment alone) in enzyme activity, respectively, after a 6-h incubation. Thus, inhibition of 5DI by these agents is due to an
enhanced rate of enzyme inactivation and/or degradation.
A striking feature of the regulation of phenolic ring deiodination in GH3 pituitary tumor cells is that exposure of intact

Table II. Effects of the In Vivo Administration of IOP on 5'DI
Activity in the Thyroid Gland of MMI-Treated Rats
Treatment

no

Va.
pmol/min * mg protein

Euthyroid
MMI controls
MMI + IOP (5 h)
MMI + IOP (12 h)

7
6
5
5

163±13
137±10
97±12§

66±7"1

A

0.09±0.01
0.12±0.01
0.11±0.01
0.12±0.02

200 Mug/ml MMI in their drinking water for 4 wk. IOP, in a single
dose of 4 mg/I00 g BW, was administered intravenously 5 or 12 h
before killing. MMI control animals were injected with an equivalent
volume of vehicle. Rats maintained for the same period on regular
drinking water served as a euthyroid group. Data represent the
mean±SE.
§ P < 0.05 vs. MMI control.
"P < 0.005 vs. MMI control. Statistical analysis was performed with
Dunnett's t test.
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Figure 6. Effects of IOP and rT3 on 5DI activity in intact, cultured
Reuber FAO hepatoma cells. FAO cells were grown to confluence in
serum-containing medium, transferred, and maintained for 24 h in
serum-free RPMI 1640 medium. IOP or rT3, in the final concentrations shown, were then added to the medium and the cells were cultured for an additional 20 h. Cells were then harvested and 5DI activity was determined in supernatant fractions of cell sonicates. The
data depicted are Eadie-Hofstee plots from a single, representative
experiment. A noncompetitive pattern of inhibition is demonstrated.
Concentrations of rT3 on the abscissa are expressed in umol/liter.
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Figure 7. The effects of
rT3 and 1OP on 5'DI activity in intact, cultured
FAO cells treated with

cycloheximide. FAO

cells were grown to confluence in serum-containing medium and
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then transferred and
IOP
rT3
maintained for 24 h in
serum-free RPMI 1640
Cycloheximide
medium. Cycloheximide (50 Ag/ml), with or without rT3 (1 uM) or lOP (10 MAM), was
then added to the medium and the cells were cultured for an additional 6 h. Cells were then harvested, and 5'DI activity was determined in supernatant fractions of cell sonicates. FAO cells maintained in serum-free medium alone served as controls. The data depicted represent the mean±SE of the pooled results from four
experiments. *P < 0.01 vs. the cycloheximide group by Dunnett's t
test.
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cells to the sulfhydryl oxidizing agent diamide results in a rapid
inactivation of 5DII activity which mimicks the effects of rT3,
IOP, and other ligands (23). Analogous findings were demonstrated in FAO hepatoma cells treated with diamide (Fig. 8). In
three experiments where intact cells were incubated for 3.5 h
with 0.4 mM diamide, 5DI Vmax levels decreased by 75±4% (P
< 0.025), whereas Km values were unaltered. Given the prior
observation that the inhibition of protein synthesis for 6 h in
FAO cells resulted in only a minimal loss of 5DI activity, the
rapidity of the diamide effect necessitates that the mechanism
involved is an enhanced rate of enzyme inactivation. In these
experiments, cells were maintained during the 3.5-h incubation period in glucose-free medium to inhibit the reformation
of glutathione (41). 5DI activity in control cells maintained in
this medium did not differ from that noted in cells maintained
concurrently in the same medium supplemented with glucose

(2 mg/ml). The inhibitory effect of diamide in these experiments was not due to interference in the in vitro 5DI assay
system; the addition of 1 mM diamide to FAO cell sonicates
did not alter 51)I activity when 20 mM DTT was present in
the reaction mixture.

Discussion
The two enzymatic pathways that convert T4 to T3 (i.e., 5DI
and 51DII) have been previously distinguished by differences in
kinetic characteristics, susceptibility to inhibition by PTU, tissue distribution, and response to alterations in thyroid hormone status (42). Whereas hyperthyroidism in the rat leads to
increased 5DI activity (5, 6), the activity of 5DII is markedly
suppressed due to an unusual, and as yet incompletely understood process, which we have termed ligand-induced inactivation (23). The seminal finding of the present studies is that
substrates and competitive inhibitors also induce the inactivation of 5DI in vivo. This finding has significant implications
for our understanding of the cellular mechanisms that regulate
thyroid hormone economy.
Inactivation of phenolic ring deiodinases. In the experiments reported herein, the administration of iodinated compounds that are devoid of thyromimetic activity (i.e., rT3 or
IOP) to experimental animals or cultured cells resulted in a
rapid and prolonged suppression of 5DI activity that was characterized by a decrease in Vm. with no change in Km. These
effects on 5DI in hepatic and renal tissue are exactly analogous
to those previously defined for 51II in the anterior pituitary
gland and cerebral cortex (23). Furthermore, the inhibitory
effects of ligands on these processes are independent of protein
synthesis and are, therefore, secondary to an enhanced rate of
enzyme inactivation and/or degradation. In the case of the
5DI present in FAO cells, rT3 and IOP enhanced the rate of
loss of enzyme activity by greater than 12-fold, assuming that
the disappearance of activity after cycloheximide treatment is

exponential.
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Figure 8. Effect of diamide on 5'DI activity in intact, cultured FAO
hepatoma cells. FAO cells were grown to confluence in serum-containing medium and then transferred and maintained for 24 h in
serum-free RPMI 1640 medium. The medium was then changed to
serum-free and glucose-free RPMI 1640, with or without diamide
(0.4 mM), and the cells incubated for an additional 3.5 h. Cells were
then washed and harvested with buffers containing 5 mM DTT and
5'DI activity was determined in the supernatant fractions of the cell
sonicates. The data depicted are Eadie-Hofstee plots from a single
representative experiment. A noncompetitive pattern of inhibition is
demonstrated. Concentrations of rT3 on the abscissa are expressed in
umol/liter.

Sato et al. (41) have previously reported that diamide
treatment impairs the conversion of T4 to T3 by intact, cultured rat hepatocytes. Their studies, however, did not determine whether the decrease in T3 formation was due to a decrease in the availability of a necessary thiol cofactor or if it
was secondary to an effect on 5DI synthesis or inactivation.
The present experiments demonstrate that this inhibitory effect of diamide on iodothyronine metabolism is due to a rapid
inactivation of 5DI. We have previously demonstrated that
ligand-induced inactivation of 5DII is also influenced by the
cellular thiol/disulfide balance; the exposure of intact GH3
cells to sulfhydryl oxidizing agents rapidly inactivates the enzyme, whereas exposure to sulfhydryl reducing agents protects
against the substrate-induced loss of activity (23). Thus, the
present finding that diamide rapidly inactivates 5DI in intact
FAQ cells provides another important parallel in the regulation of the two phenolic ring deiodinase processes.
Of note, however, is that the 5DI process appears to be
considerably less sensitive than the 5DII one to ligand-induced
inactivation. Under experimental conditions where enzyme
activity is increased (hypothyroidism for 5DII; hyperthyroidism for 5DI), a single injection of 0.04 mg IOP/00 g BW
inactivates > 80% of 5DII in the anterior pituitary gland and
cerebral cortex (23), yet has no effect on 51)I in the liver or
Regulation of Type I Iodothyronine S'-Deiodinase
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kidney (Fig. 3). Indeed, a 70-80% inhibition of 5DI activity is
only achieved when hypothyroid or hyperthyroid rats are administered a 100-fold larger dose of IOP (Table I and Fig. 3).
Similarly, a single dose of rT3 of 50 ztg/ 100 g BW, which has
been demonstrated by other investigators to inhibit 5DII activity in the pituitary gland and cerebral cortex by > 90% (43),
had no effect on 5DI activity when administered to hyperthyroid animals in the present studies. Results from our cell culture studies provide additional evidence that 5DI is less sensitive to ligand-induced inactivation. We have previously demonstrated that the concentration of IOP required to inhibit
5DII activity by 50% in intact GH3 cells that are maintained in
serum-free medium is 0.005 IAM (23). In the present experiments using FAO cells grown under analogous conditions,
50% inhibition of 5DI required a medium IOP concentration
of 0.5 gm.
Taken together, these data suggest that 100-fold greater
concentrations of ligand are required to inactivate 5'DI as
compared with 5DIL. The reason for this marked difference in
susceptibility to inactivation is uncertain, but could reflect tissue differences in either ligand concentration or the thiol/disulfide balance. Another intriguing possibility is suggested by
our previous observation that the potency of a ligand in inactivating 5DII in intact GH3 cells is closely correlated with the
ligand's Ki value as determined in broken cell preparations and
indicative of the affinity of the ligand for the enzyme's active
site (23). The Ki values ofIOP for 51)I and 5DII are 8 AM (Fig.
1) and 0.05 ,M (23), respectively, and therefore the affinity of
51)I for this ligand is about two orders of magnitude less than
the affinity of 5DIL. Thus, if the cellular mechanisms that
inactivate 5DI and 5DII are similar, the lesser potency of IOP
that inactivates the former enzyme may reflect the fact that
higher concentrations are required to interact with the 51DI
active site and to initiate the inactivation process.
In addition to this difference in sensitivity, ligand-induced
inactivation of 5DI is somewhat slower than that noted for
5DI. In intact GH3 cells, maximal inactivation of 5DII by
ligands is noted after a 1-2-h incubation period (23), whereas
in the FAO cells used in the present experiments, a 3-h incubation period with rT3 or IOP resulted in only half-maximal
inhibitory effects. Of further note is that compared with the
50-min half-life of 5DII activity in GH3 cells and other rat
tissues (44), the turnover of 5DI in FAO cells appears to be
considerably slower, with only a 5% loss of enzyme activity
after a 6-h treatment of cells with cycloheximide.
Dual mechanism of control of 5'DI by iodinated compounds. The present results demonstrate that iodothyronines
and other iodinated compounds have complex regulatory effects on 5DI in the liver and kidney. As demonstrated herein,
and previously reported by other investigators (4-6), 5DI is
activated by the chronic administration of the metabolically
active thyroid hormones T3 or T4. Ligands for the enzyme
which have little or no thyromimetic activity (i.e., rT3 and
IOP), however, inactivate this enzymatic process and can,
when present in high concentrations, counteract the stimulatory effects of T3 on 5DI. Whether this activation and inactivation represent changes in enzyme synthesis and degradation
remains uncertain.
Over the last three decades, investigators have observed
that the administration of rT3 to patients or laboratory animals, in amounts considerably larger than those used in the
present study, counteracts the thyrotoxic state and antagonizes
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the effects of T4 (45-48). Such treatment has also been demonstrated to decrease hepatic T4 to T3 conversion (49), an effect
which has previously been attributed to the competitive effect
of rT3 on T4 deiodination that was noted in vitro (10, 50).
Recently, Han et al. (51) reported that rT3 also antagonizes the
induction of 5DI by insulin, cortisol, and T3 in cultured fetal
mouse liver cells. It was uncertain from their study, however,
which processes mediated this rT3 effect. The present findings
provide a better understanding of the cellular mechanisms that
underlie these observations. Our findings do not negate the
possibility that rT3, when present in high concentrations,
competes in vivo with T4 as a substrate for phenolic ring deiodination. Rather, our results suggest that in so doing, the large
ligand load presented by rT3 rapidly inactivates 51DI, and that
this is likely to contribute significantly to the impairment observed in T3 production.
Radiographic contrast agents for the treatment for hyperthyroidism. Radiographic contrast agents have been used successfully to treat the hyperthyroid state that accompanies
Graves' disease in adults (13, 14, 17). Recent reports have also
demonstrated the therapeutic value of administering these
agents to patients with neonatal Graves' disease (52) and thyrotoxicosis factitia (53). IOP and NaIp offer several practical
advantages when used as treatments for these conditions. They
can be administered infrequently (13, 14), are generally well
tolerated during chronic therapy (14), and rarely cause hypersensitivity reactions (52). In addition, the rapidity with which
serum T3 levels are lowered may have important clinical benefits (17).
The present findings provide new insights into the mechanisms whereby radiographic contrast agents alter thyroid hormone economy in thyrotoxicosis. The inactivating effect of
IOP on 5DI in hyperthyroid rats was noted to be rapid in onset
and long-lasting in duration. Maximal inactivation was noted
within 5 h, and significant effects persisted for 60 h after a
single dose despite continued T3 administration. In the clinical
setting, the inhibitory effect would be likely to persist even
longer, as the rapid lowering of serum and tissue T3 levels
would decrease the stimulus for 5DI activation. These results
correlate well with clinical observations that serum T3 levels in
hyperthyroid patients decrease 60% during the first 24 h of
treatment with these agents (15, 16) and that they need be
administered only once every 3 d (13).
In a recent study, Wang et al. (54) reported that a fixed
dose of IOP (500 mg/d and equivalent to -1 mg/100 g BW in
the patients studied) resulted in the long term normalization of
serum T3 concentrations in only 45% of patients with Graves'
disease. Given the present finding that the inactivating effects
of radiographic contrast agents on 5DI are dose-dependent,
the therapeutic use of these agents in treating hyperthyroidism
may require that the dosage be titrated to achieve optimal
effects.
The thyroid gland in patients with Graves' disease demonstrates increased 51DI activity (36, 37) and enhanced secretion
of T3 (55). Indeed, Laurberg (56) has recently demonstrated
that both endogenous T4 (that is, T4 derived from thyroglobulin) and circulating T4 are deiodinated to T3 in this organ. The
present finding that 5DI in the thyroid gland is also subject to
rapid inactivation by IOP provides an explanation for the previous observations that radiographic contrast agents inhibit
thyroidal T3 secretion in vivo (57) and 51DI activity in vitro
(38, 58).

In conclusion, we have demonstrated that 5DI is subject to
ligand-induced inactivation, an observation which corrects
prior misconceptions concerning the mechanism whereby iodothyronines and other iodinated compounds inhibit T4 to T3
conversion in vivo. Although this inactivation process appears
to be analogous to that previously delineated for 5DII, the role
of this mechanism in regulating the activity of these two enzymatic pathways appears to differ. Whereas inactivation by
substrate is the principal mechanism controlling 5DII activity
(44), it seems unlikely that this process influences 5DI activity
under physiologic or even pathologic conditions; the predominant effect of T4 on 5DI is one of activation (5, 6, 59) and rT3
concentrations are probably insufficient to exert a significant
inactivating effect (49). However, the inactivation of 5DI is of
major pharmacologic importance when the radiographic contrast agents are used to treat hyperthyroid patients. At present,
the biochemical processes that mediate the inactivation of the
phenolic ring deiodinases remain uncertain. A greater understanding of this unusual mechanism of enzyme regulation is
likely to have important theoretical and clinical consequences.
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